Catalyst
Slingshot members are tracking this event:
Phase 2 data of Fostamatinib for IgA nephropathy due by the end of 2016
Do you think this event is important to the companies below? How will it affect their stock price?
Related Companies | Importance
|
Impact on Stocks
|
||||
---|---|---|---|---|---|---|
RIGL | Community voting in process |
Additional Information
Disease background: IgAN is an autoimmune disease that severely affects the functioning of the kidneys. An estimated 12,000 Americans are diagnosed with this type of glomerulonephritis each year, with 25% of its victims eventually requiring dialysis and/or kidney transplantation over time. IgAN is characterized by the deposition of IgA immune complexes in the glomeruli of the kidneys leading to an inflammatory response and subsequent tissue damage that ultimately disrupts the normal filtering function of the kidneys. By inhibiting SYK in kidney cells, fostamatinib may block the signaling of IgA immune complex receptors and arrest or slow destruction of the glomeruli.
Orally-available SYK inhibitor program: We have a Phase 2 clinical trial in patients with IgAN. We expect the clinical trial, called SIGN (SYK Inhibition for Glomerulonephritis), to enroll about 25 patients with the disease and report results by the end of 2016.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jan 11, 2017
Occurred Source:
http://ir.rigel.com/phoenix.zhtml?c=120936&p=irol-EventDetails&EventId=5245849
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 2 Data, Fostamatinib, Iga Nephropathy